ALT Stock Summary and Trading Ideas (Altimmune | NASDAQ:ALT)

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune trades on the NASDAQ stock market under the symbol ALT.

As of March 12, 2026, ALT stock price declined to $3.60 with 2,748,155 million shares trading.

ALT has a beta of 0.96, meaning it tends to be less sensitive to market movements. ALT has a correlation of 0.02 to the broad based SPY ETF.

ALT has a market cap of $450.83 million. This is considered a Small Cap stock.

Last quarter Altimmune reported $26,000 in Revenue and -$.27 earnings per share. This beat revenue expectation by $25,440 and missed earnings estimates by -$.02.

In the last 3 years, ALT traded as high as $14.84 and as low as $2.09.

The top ETF exchange traded funds that ALT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.

ALT has underperformed the market in the last year with a price return of -35.1% while the SPY ETF gained +20.5%. ALT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.7% and -19.3%, respectively, while the SPY returned -2.0% and -3.4%, respectively.

ALT support price is $3.67 and resistance is $3.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALT shares will trade within this expected range on the day.